Idarubicine
Adult Acute Myeloid Leukemia With Del(5q)
Bruno C. MedeirosPhase 2Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Adult Acute Myeloid Leukemia With Del(5q) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Alice Mims | Phase 3 | BBB |
Cytosin-Arabinosid Alice Mims | Phase 3 | BBB |
Cyclophosphamide Sumithira Vasu | Phase 3 | BBB |
Fludarabine Rutgers, The State University of New Jersey | Phase 3 | BBB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →